Rocket Pharmaceuticals Shares Slide After FDA Rejects Kresladi
By Colin Kellaher
Rocket Pharmaceuticals shares fell after the Food and Drug Administration declined to approve the company's proposed treatment for the rare pediatric immunodeficiency disorder leukocyte adhesion deficiency-I.
Shares of the Cranbury, N.J., biotechnology company were recently changing hands at $19.99, down 6.7%.
Rocket on Friday said the FDA requested limited additional information related to chemistry, manufacturing and controls to complete its review of marnetegragene autotemcel, which the company plans to market as Kresladi.
In a research note, analysts at William Blair said they believe Rocket will quickly resolve the request and resubmit its application for Kresladi in a timely manner, and that they are confident of an FDA approval for the gene therapy.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 28, 2024 10:25 ET (14:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
United States